Arsanis (NASDAQ:ASNS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, March 16th.
According to Zacks, “Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company’s product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. “
Several other research firms have also weighed in on ASNS. Cantor Fitzgerald set a $26.00 target price on shares of Arsanis and gave the company a “buy” rating in a report on Thursday, March 15th. Piper Jaffray assumed coverage on shares of Arsanis in a research note on Monday, December 11th. They issued an “overweight” rating and a $23.00 price target on the stock. Cowen assumed coverage on shares of Arsanis in a research note on Monday, December 11th. They issued an “outperform” rating on the stock. Citigroup assumed coverage on shares of Arsanis in a research note on Monday, December 11th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, ValuEngine raised shares of Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Arsanis has a consensus rating of “Buy” and a consensus price target of $25.75.
ASNS opened at $22.30 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.45 and a quick ratio of 7.45. Arsanis has a 12-month low of $10.40 and a 12-month high of $28.69.
Arsanis (NASDAQ:ASNS) last posted its earnings results on Friday, March 9th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.82). analysts forecast that Arsanis will post -4.57 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in ASNS. Monashee Investment Management LLC acquired a new stake in Arsanis during the 4th quarter worth $191,000. Millennium Management LLC acquired a new position in shares of Arsanis during the 4th quarter valued at about $299,000. Landscape Capital Management L.L.C. acquired a new position in shares of Arsanis during the 4th quarter valued at about $504,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Arsanis during the 4th quarter valued at about $3,436,000. 69.45% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/arsanis-asns-downgraded-to-hold-at-zacks-investment-research.html.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.
Get a free copy of the Zacks research report on Arsanis (ASNS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.